12th International Symposium

GRAFT VERSUS HOST

GvH/GvL

GRAFT VERSUS LEUKEMIA

GvH/GvL 2014

Thon-Dittmer Palais Regensburg, Germany

March 26 to 28, 2014

Competence Center
Department of Hematology & Oncology
University Hospital Regensburg
Local Scientific committee

Ernst Holler
Wolfgang Herr
Matthias Edinger
Daniel Wolff
Petra Hoffmann
Marina Kreutz
Reinhard Andreesen
Hans-Jochem Kolb

Supported by
Dear colleagues,

It is our great honour and pleasure to welcome you again for the 12. GvH/GvL meeting in our historical city of Regensburg. Since the first GvH/GvL meeting held in Munich the idea of a focussed meeting allowing extensive exchange and discussion among experts and young interested colleagues and on site development of concepts and ideas seems to meet the needs and the interest of many colleagues involved in the field of allogeneic stem cell transplantation and clinical immunobiology. Therefore, we are very grateful that so many distinguished experts from all over the world have immediately accepted our invitation to contribute as speakers, chairs and discussants to the success of the 2014 meeting.

We hope that you enjoy our meeting and your visit in Regensburg

Ernst Holler, MD                          Wolfgang Herr, MD
Wednesday March 26

11.00  Registration

12.00 – 13.00  Satellite symposium

(sponsored by Chugai Pharma Marketing LTD)

Chair: Wolfgang Herr

12.00 – 12.30  G-CSF - short and long term safety aspects in stem cell transplantation
Kristina Hölig (Dresden)

12.30 – 13.00  Quo Vadis - haploidential stem cell transplantation?
Lutz Uharek (Berlin)

13.00 – 14.00  Welcome Lunch
Wednesday March 26

14.00 - 14.15  Welcome

14.15 - 16.45  Session I

Biomarkers and predictors of GvHD
Chairs: Jürgen Finke, Nikolaus Kröger

14.15-14.45  A new grading system for acute GvHD based on biomarkers
James LM Ferrara (Ann Arbor)

14.45-15.15  Urinary proteomics to predict acute and chronic GvHD
Eva Maria Weissinger (Hannover)

15.15-15.45  Biomarkers of chronic GvHD
Daniel Wolff (Regensburg)

15.45-16.15  miRNAs in GvHD
Anne Dickinson (Newcastle)

16.15-16.45  HLA-DP and GvHD
Katharina Fleischhauer (Essen)

16.45 - 17.15  Coffee Break

17.15 - 18.15  Keynote Lecture
Chair: Daniela Männel

Innate Lymphoid Cells and their role in intestinal inflammation
Andreas Diefenbach (Freiburg)

19.00 – 21.00  Evening discussion (with beer and brezels)

Everything you always wanted to know about GvHD* (*but were afraid to ask):
Young scientists challenge the experts
# Thursday, March 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30-10.50</td>
<td>Session II</td>
<td>Key players in intestinal inflammation and GvHD</td>
<td>Chairs: Armin Gerbitz, Ralf Meyer</td>
</tr>
<tr>
<td>8.30-8.55</td>
<td></td>
<td>Nutrition, microbiome and GvHD</td>
<td>Marcel v d Brink (New York)</td>
</tr>
<tr>
<td>8.55-9.20</td>
<td></td>
<td>Reciprocal expression of antibacterial peptides in GvHD</td>
<td>Takanori Teshima (Sapporo)</td>
</tr>
<tr>
<td>9.20-9.45</td>
<td></td>
<td>Reg3a, defensins and microbiota in human GvHD</td>
<td>Ernst Holler (Regensburg)</td>
</tr>
<tr>
<td>9.45-10.10</td>
<td></td>
<td>Retinoic acid in intestinal GvHD</td>
<td>Bruce Blazar (Minnesota)</td>
</tr>
<tr>
<td>10.10-10.35</td>
<td></td>
<td>Tregs in intestinal GvHD</td>
<td>Petra Hoffmann (Regensburg)</td>
</tr>
<tr>
<td>10.35-10.50</td>
<td></td>
<td>Mapping of immune responses</td>
<td>Andreas Beilhack (Würzburg)</td>
</tr>
<tr>
<td>10.50-11.30</td>
<td>Coffee</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.30-13.10</td>
<td>Session III</td>
<td>APCs in GvHD:</td>
<td>Chairs: Andreas Mackensen, Reinhard Andreesen</td>
</tr>
<tr>
<td>11.30-11.55</td>
<td></td>
<td>DAMPs activating APCs during GvHD</td>
<td>Robert Zeiser (Freiburg)</td>
</tr>
<tr>
<td>11.55-12.20</td>
<td></td>
<td>Licensing of T cells by APCs</td>
<td>Ron Chakraverty (London)</td>
</tr>
<tr>
<td>12.20-12.45</td>
<td></td>
<td>Human DC subsets in GvHD</td>
<td>Matthew Collin (Newcastle)</td>
</tr>
<tr>
<td>12.45-13.10</td>
<td></td>
<td>Chronic lung injury after allogeneic HCT – lessons to learn</td>
<td>Gerhard Hildebrandt (Salt Lake City)</td>
</tr>
<tr>
<td>13.10 - 14.30</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
14.30 - 16.00  Session IV

Sponsored by the KFO 146
“Cell-mediated suppression of auto- and alloreactive immune responses”

B cells in GvHD:
Chairs: Matthias Edinger, Hildegard Greinix

14.30-15.00  Plasma cells in autologous BMT & autoimmune diseases
Andreas Radbruch (Berlin)

15.00-15.30  B cell reconstitution & infectious immunity after allogeneic BMT
Thomas Winkler (Erlangen)

15.30-16.00  HY-specific B cells
David Miklos (Stanford)

16.00 - 16.30  Coffee Break

16.30-17.30  Sessions V

New approaches in GvH and GvL
Chair: Hans Jochem Kolb, Selim Corbacioglu

16.30-17.00  IL6-blockade: Experimental rationale and first clinical results
Geoffrey Hill (Brisbane)

17.00-17.30  B and T cell receptor sequencing in GvH and GvL
Edus Warren (Seattle)

17.30-18.00  Hans Jochem Kolb Award
Friday, March 28

8.30 - 10.35  Session VI

Cellular therapy:
Chairs: Lutz Uharek, Martin Bornhäuser

- in GvHD:

8.30-8.55  Regulatory T cells
Matthias Edinger (Regensburg)

8.55-9.20  Mesenchymal stem cells
Katarina Le Blanc (Stockholm)

- in GvL:

9.20-9.45  Naive vs Memory T cells
Wolfgang Herr (Regensburg)

9.45-10.10  CD4 cells recognizing DP: Balancing between GvL and GvHD
Fred Falkenburg (Leiden)

- in infections:

10.10-10.35  Multi-virus-specific T cells
Armin Gerbitz (Erlangen)

10.35-11.00  Coffee Break

11.00 - 13.05  Session VII

Perspectives of cellular therapy
Chairs: Wolfgang Herr, Hermann Einsele

11.00-11.25  CAR modified T cells targeting CD19
Renier J. Brentjens (New York)

11.25-11.50  ROR1 CAR for targeted T cell therapy
Michael Hudecek (Würzburg)

11.50-12.15  Memory stem T cells
Chiara Bonini (Mailand)

12.15-12.40  gamma/delta T cells
Jürgen Kuball (Utrecht)

12.40-13.05  NPM1mut specific T cells
Michael Schmitt (Heidelberg)

13.05  Farewell
This symposium would not have been possible without the generous support with unrestricted educational grants from:

25,000 Euro / Neovii Biotech GmbH
15,000 Euro / Amgen GmbH
1,500 Euro / Alexion Pharma Germany GmbH
3,000 Euro / Bristol Myers Squibb
1,500 Euro / Celgene GmbH
3,000 Euro / Chugai Pharma Marketing Ltd.
1,000 Euro / Gilead Sciences GmbH
2,000 Euro / Hexal GmbH
1,000 Euro / Janssen Cilag
3,000 Euro / Medac GmbH
3,000 Euro / Miltenji Biotech
2,000 Euro / MSD GmbH
2,500 Euro / Novartis Pharma GmbH
2,000 Euro / Novartis Pharma GmbH Transplantation
5,000 Euro / Riemser GmbH
5,000 Euro / Roche GmbH
2,000 Euro / Takeda GmbH
2,000 Euro / Therakos UK Limited
3,000 Euro / TEVA GmbH
Conference Venue:
Thon Dittmer Palais
Haidplatz 8
93047 Regensburg

General tourist and hotel information:
Tourist Information Altes Rathaus
Rathausplatz 1
93047 Regensburg
Germany
Tel.: +49(0)941/507-4410
Fax: +49(0)941/507-4411
http://www.tourismus-regensburg.de

Local Contact
Gertraud Geißler/Susanna Blüml
Department of Medicine III
University Hospital Regensburg
Germany
Tel.: *49/941/944-5501 or -5542
Email: gertraud.geissler@ukr.de or susanna.blueml@ukr.de

Airport
International Franz-Josef-Strauß-Airport Munich
Airport Nürnberg
12th International Symposium

GvH GvL 2014
Thon-Dittmer Palais Regensburg
March 26 to 28, 2014

Evening Activities

Dinner at „Haus Heuport“
Domplatz 7, 93047 Regensburg
19:00 Uhr, Thursday, March 27, 2013
Location Thon-Dittmer-Palais Regensburg